Delivery Order SPE2DB22D2206-SPE2DB25FJP44
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $18,617.58 to AmerisourceBergen Drug Corp for CABENUVA ER 600 MG-900 MG suspension (6 mL) with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation, performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. CABENUVA is a long-acting injectable antiretroviral medication used in HIV treatment, reflecting the Defense...
- The Defense Logistics Agency awarded a $38,169.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for CABENUVA ER 600 MG-900 MG suspension (6 mL), with an ultimate completion date of May 15, 2025. This non-set-aside competitive award represents a child delivery order against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $3,816.90 to supply CABENUVA ER 600 MG-900 MG Suspension 6ML, a long-acting injectable antiretroviral medication used for HIV treatment. This firm fixed price, competitively awarded delivery order is scheduled for completion by July 14, 2025, and is being performed from AmerisourceBergen's location in Conshohocken, Pennsylvania. The contract is part of the company's broader pharmaceutical...
- The Defense Logistics Agency awarded a $7,633.80 delivery order to AmerisourceBergen Drug Corp for CABENUVA ER 600 MG-900 MG suspension (6 mL) with a firm fixed price structure and an ultimate completion date of August 20, 2025. This non-set-aside, competitively awarded contract represents a single delivery order executed on July 30, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. CABENUVA is an injectable antiretroviral...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of CABENUVA ER (cabotegravir/rilpivirine) 600 mg-900 mg suspension in 6 mL vials, valued at $38,169.00. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The contract has an ultimate completion date of October 3, 2025, and will be performed at the awardee's location in...
- The Defense Logistics Agency awarded a delivery order valued at $34,352.10 to AmerisourceBergen Drug Corp for CABENUVA ER 600 MG-900 MG suspension (6 mL), a long-acting injectable antiretroviral medication used in HIV treatment. This firm fixed-price delivery order, issued on June 2, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 through December 2026. The contract carries...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $30,535.20 to AmerisourceBergen Drug Corp for CABENUVA ER 600 MG-900 MG suspension (6 mL), a long-acting antiretroviral combination medication used in HIV treatment. Issued on September 14, 2025, with an ultimate completion date of October 3, 2025, this firm fixed-price delivery order represents a routine pharmaceutical procurement under a competitive award with no set-aside designation. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $38,169.00 to AmerisourceBergen Drug Corp for CABENUVA ER 600 mg–900 mg suspension (6 mL) with a completion date of September 30, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed-price pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a...
- The Defense Logistics Agency awarded a $59,619.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for CABENUVA ER 400 MG-600 MG suspension (4 mL), a long-acting injectable antiretroviral medication. The contract, issued on August 29, 2025, with ultimate completion by September 22, 2025, represents a non-competitive, non-set-aside award leveraging the vendor's existing DLA contract vehicle. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $22,901.40 to AmerisourceBergen Drug Corp for CABENUVA ER 600 mg-900 mg suspension in 6 ml quantities. This is a firm fixed price, competitively awarded delivery order with an ultimate completion date of August 15, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents a child order under a larger contracting vehicle. No set-aside designation was applied to this...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJP44Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,169 to AmerisourceBergen Drug Corp for CABENUVA ER 600 mg-900 mg suspension (6 mL) on August 22, 2025. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 15, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. CABENUVA is a long-acting injectable antiretroviral medication used in HIV treatment, representing the company's continued role as a critical pharmaceutical supplier to federal healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. AmerisourceBergen, one of the nation's largest pharmaceutical distributors, serves as a prime vendor for the Defense Health Agency and other federal healthcare systems, supplying a comprehensive portfolio of brand-name and generic medications, vaccines, and medical devices across multiple therapeutic areas. The company's competitively awarded contracts demonstrate its capability to meet rigorous federal procurement requirements for supporting military and veteran healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $38.2k | 8/22/25 |